ZUG, Switzerland and BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
Vertex has entered a reimbursement agreement with NHS England enabling eligible SCD patients to access Casgevy in the public ...
Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...
Bernstein SocGen Group adjusted its price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), increasing it slightly from $441.00 to $444.00 while maintaining a Market Perform rating. With a ...
An estimated 12,000 children are born with thalassemia major, a severe form of the disease, in India each year, accounting ...
Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...
To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...
The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...
With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback